PARIS & BOULDER, Colo.--(BUSINESS WIRE)--Regulatory News:
SpineGuard (FR0011464452 – ALSGD) (Paris:ALSGD), an innovative company that deploys its DSG® (Dynamic Surgical Guidance) sensing technology to secure and streamline the placement of bone implants, confirms that its Annual Shareholders meeting will be held on Thursday 14 May, 2020 at 08:45 CEST in a closed virtual session.
In compliance with recent French legislation1 and per the recommendations of the French SEC (Autorité des Marchés Financiers or AMF), SpineGuard confirms that its Annual Ordinary and Extraordinary Shareholders Meeting will take place on May 14, 2020 at 8:45 am (CEST) in a closed virtual session. It is hereby reminded that AMF strongly encourages the shareholders to vote, such right being a fundamental prerogative of each shareholder.
Such right shall be exclusively exercised through a vote by proxy and, except for particular cases, prior to the shareholders meeting taking place.
Documents including the shareholders brochure (‘brochure de convocation’ in French only) and the voting form are available at the following links:
In order to be taken into account a shareholding certificate issued by the shareholders broker shall be sent with the voting form. The voting form and the holding certificate shall be either mailed to Société Générale, Services Assemblée Générale, 32 rue du Champ de Tir – CS 30812, 44308 Nantes Cedex 3 or e-mailed to email@example.com
Deadline for reception is 11 May 2020
The Shareholders Meeting will be webcasted at https://global.gotomeeting.com/join/630832325
The shareholders presentation will be released on the company’s web site at 8:45 am (CEST) on the day of the meeting at https://www.spineguard.com/fr/investisseurs/documentation/
Founded in 2009 in France and the USA by Pierre Jérôme and Stéphane Bette, SpineGuard is an innovative company deploying its proprietary radiation-free real time sensing technology DSG® (Dynamic Surgical Guidance) to secure and streamline the placement of implants in the skeleton. SpineGuard designs, develops and markets medical devices that have been used in over 75,000 surgical procedures worldwide. Fifteen studies published in peer-reviewed scientific journals have demonstrated the multiple benefits DSG® offers to patients, surgeons, surgical staff and hospitals. Building on these solid fundamentals and several strategic partnerships, SpineGuard has expanded its technology platform in a disruptive innovation: the « smart » pedicle screw launched late 2017 and is broadening the scope of applications in dental implantology and surgical robotics. DSG® was co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer.
For further information, visit www.spineguard.com
The SpineGuard securities may not be offered or sold in the United States as they have not been and will not be registered under the Securities Act or any United States state securities laws, and SpineGuard does not intend to make a public offer of its securities in the United States. This is an announcement and not a prospectus, and the information contained herein does and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in the United States in which such offer, solicitation or sale would be unlawful prior to registration or exemption from registration.
1 bill of 23 March 2020 to respond to COVID-19 and decree dated 25 March